Skip to content

H.R. 1076 · 118th Congress (2023–2025)

Preventing the Financing of Illegal Synthetic Drugs Act

This bill requires the Government Accountability Office to carry out a study on illicit financing in connection with the trafficking of synthetic drugs, including fentanyl and methamphetamine, fentanyl- and methamphetamine-related substances, Captagon, and fentanyl and methamphetamine precursors, and to report to Congress.

Show official title

To require the Comptroller General of the United States to carry out a study on the trafficking into the United States of synthetic drugs, and related illicit finance, and for other purposes.

Enacted

Public law number: P.L. 118-79

This bill’s path

574 days after it was introduced

This is H.R. 1076’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced3 months

  2. Passed House14 months

  3. Passed Senate

  4. Resolving differences

    Not neededsame bill text

  5. Sent to President

  6. Signed into law

Sponsor
Rep. Monica De La Cruz (R-TX-15)
Cosponsors
8 cosponsors

2 original · 6 later

5 R · 3 D

  1. Rep. Andrew Ogles (R-TN-5)· Original · Feb 17, 2023
  2. Rep. Brittany Pettersen (D-CO-7)· Original · Feb 17, 2023
  3. Rep. Lori Chavez-DeRemer (R-OR-5)· Later · Feb 28, 2023
  4. Rep. Michael Lawler (R-NY-17)· Later · Feb 28, 2023
  5. Rep. Byron Donalds (R-FL-19)· Later · May 22, 2023
  6. Rep. Marie Gluesenkamp Perez (D-WA-3)· Later · May 22, 2023
  7. Rep. Chris Pappas (D-NH-1)· Later · May 22, 2023
  8. Rep. Bryan Steil (R-WI-1)· Later · May 22, 2023
Policy area
Government Operations and Politics
Subjects
  • Congressional oversight
  • Drug trafficking and controlled substances
  • Fraud offenses and financial crimes
  • Government studies and investigations
  • Internet, web applications, social media
  • Smuggling and trafficking

On this page

Spending

The enacted law text (Public Law 118–79) is not available locally.

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

Jump to latest
  1. Introduced in House

    Document: Introduced in House

    Sources
  2. ▸ 6 committee actions · Feb 17, 2023 – May 22, 2023
    1. Referred to committee

      Referred to the Committee on Financial Services, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Markup session held

      Committee Consideration and Mark-up Session Held.

      Sources
    4. Ordered reported

      Ordered to be Reported in the Nature of a Substitute (Amended) by Voice Vote.

      Sources
    5. Committee discharged

      Committee on Energy and Commerce discharged.

      Sources
    6. Reported by committee

      Reported (Amended) by the Committee on Financial Services. H. Rept. 118-75, Part I.

      Sources
  3. Passed House

    Roll call 228

    Congressional Record H2469

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 402 - 2 (Roll no. 228).

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources
  4. ▸ 2 committee actions · May 30, 2023 – Jul 23, 2024
    1. Referred to committee

      Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

      Sources
    2. Committee discharged

      Senate Committee on Banking, Housing, and Urban Affairs discharged by Unanimous Consent.

      Sources
  5. Passed Senate

    Congressional Record S5319; text: CR S5319

    Passed Senate without amendment by Unanimous Consent.

    The Senate passed the bill.

    Sources
  6. Enrolled Bill

    Congress published an enrolled text of the bill.

    Document: Enrolled Bill

    Sources
  7. Presented to the President

    Presented to President.

    Sources
  8. Latest

    Law

    Signed by President

    Became Public Law 118–79.

    Document: Public Law

    Sources

Roll-call votes

  1. House roll call 228Passed

    On Motion to Suspend the Rules and Pass, as Amended

    402–2

Committees

  1. HouseFinancial ServicesReferred Feb 17, 2023 · Markup Feb 28, 2023 · Reported May 22, 2023H. Rept. 118-75
    1. Feb 28, 2023 · Markup

    1. H. Rept. 118-75 · May 22, 2023 · Preventing the Financing of Illegal Synthetic Drugs Act
  2. HouseEnergy and CommerceReferred Feb 17, 2023
  3. HouseHealthReferred Feb 24, 2023
  4. HouseJudiciaryReferred Feb 17, 2023
  5. SenateBanking, Housing, and Urban AffairsReferred May 30, 2023

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. May 22, 2023 · House · Considered as unfinished businessCongressional Record H2483

    Announcement by the Speaker Pro Tempore

  2. May 22, 2023 · House · Considered under suspension of the rulesCongressional Record H2469–H2471

    Preventing the Financing of Illegal Synthetic Drugs Act

  3. May 22, 2023 · House · Considered as unfinished businessCongressional Record H2483

    Preventing the Financing of Illegal Synthetic Drugs Act

  4. Jul 23, 2024 · Senate · Passed Senate without amendment by Unanimous ConsentCongressional Record S5319

    Preventing the Financing of Illegal Synthetic Drugs Act

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Engrossed in House
Referred in Senate
Public Law
Enrolled Bill—
Titles (2)
  1. Preventing the Financing of Illegal Synthetic Drugs Act

    Short title, Display title · Enrolled Bill, Referred in Senate, Introduced in House, Reported in House, Engrossed in House

  2. To require the Comptroller General of the United States to carry out a study on the trafficking into the United States of synthetic drugs, and related illicit finance, and for other purposes.

    Official title · Introduced in House